EBS News and Press, Emergent Biosolutions Inc. From 03/11/20

Emergent BioSolutions (NYSE: EBS ) initiates two new programs aimed at treating and preventing coronavirus infection based on its hyperimmune platforms. More news on: Emergent BioSolutions Inc., Healthcare stocks news, Stocks on the move, Read more ...

Human polyclonal hyperimmune with antibodies to SARS-CoV-2 (COVID-HIG) being developed as a potential treatment for severe hospitalized patients and protection for at-risk individuals Equine-derived polyclonal hyperimmune with antibodies to SARS-CoV-2 (COVID-EIG) being developed as a pot...

Shares of Emergent BioSolutions (NYSE: EBS) jumped 10.2% on Tuesday after the bioterrorism expert said that it's working with Novavax (NASDAQ: NVAX) to develop its vaccine against the coronavirus that causes COVID-19. The announcement shouldn't have come as much of a surprise. On its ...

Novavax (NASDAQ: NVAX) , a clinical-stage biotechnology company, is currently perceived as one of the leaders in the race to develop a vaccine for COVID-19. The company recently announced it received a grant of $4 million from the Coalition for Epidemic Preparedness Innovations (CEPI) to supp...

The Coalition for Epidemic Preparedness (CEPI) has awarded $4M to Novavax (NASDAQ: NVAX ) to support the development of a COVID-19 vaccine. It is currently assessing multiple candidates in animal models. More news on: Novavax, Inc., Emergent BioSolutions Inc., Healthcare stocks news, Sto...

GAITHERSBURG, Md., March 10, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has entered into an agreement with Novavax, Inc. (NASDAQ:NVAX) whereby Emergent will collaborate with Novavax, utilizing its molecule-to-market contract development and manufa...

Whatever happened to healthcare companies being recession resistant? On Monday, shares of Emergent Biosolutions (NYSE: EBS) fell 10.5%, BioMarin Pharmaceuticals (NASDAQ: BMRN) dropped 10.1%, and NuVasive (NASDAQ: NUVA) fell 10.2%, all more than the S&P 500, which slipped 7.6% ...

Emergent BioSolutions (NYSE: EBS) reported fourth-quarter earnings that beat top-line expectations but missed on profit estimates. The company, which focuses on drugs, vaccines, and medical devices that address  emerging public health threats , grew its revenue by 33% to $360.4 mil...

Emergent BioSolutions Inc. (EBS) Q4 2019 Earnings Conference Call February 20, 2020 5:00 P.M. ET Company Participants Bob Burrows - Vice President, Investor Relations Bob Kramer - President and Chief Executive Officer Rich Lindahl - Chief Financial Officer Conference Call Part...

Emergent Biosolutions (NYSE: EBS ): Q4 Non-GAAP EPS of $1.57 beats by $0.70 ; GAAP EPS of $0.89 beats by $0.02 . More news on: Emergent BioSolutions Inc., Earnings news and commentary, Healthcare stocks news, Read more ...